Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
Active, not recruiting · NCT03233347 · Registry updated 2026-09-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma | classic Hodgkin lymphoma | Active, not recruiting | Phase 2 | 2026-09-15 | NCT03233347 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Academic and Community Cancer Research United | 13 |
| National Cancer Institute (NCI) | 3015 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Carolinas Medical Center/Levine Cancer Institute | Charlotte | United States | 149 |
| City of Hope Comprehensive Cancer Center | Duarte | United States | 263 |
| Hackensack University Medical Center | Hackensack | United States | 308 |
| M D Anderson Cancer Center | Houston | United States | 667 |
| Mayo Clinic in Rochester | Rochester | United States | 687 |
| University of Nebraska Medical Center | Omaha | United States | 397 |
| University of Pennsylvania/Abramson Cancer Center | Philadelphia | United States | 118 |
| University of Washington Medical Center - Montlake | Seattle | United States | 121 |
| Vanderbilt University/Ingram Cancer Center | Nashville | United States | 259 |